Newborn, Parturient
Conditions
Keywords
Tryptase, Neonatal, Newborn, Transplacental passage, Mast cell, Inflammation, Biomarker
Brief summary
Currently the neonatal serum level of severals proteins can be used as an indicator of subsequent risk. For example, we plan to explore the neonatal kinetics of tryptase and other immune proteins as potential markers for the risk of postnatal complications, particularly in premature babies. However, today no study has shown whether the tryptase level in the newborn is a reflection of fetal synthesis alone, or that of the mother by possible transplacental passage. There is also no database that has defined normal values for tryptase in cord blood. Our main objective is to determine the correlation between the level of maternal tryptase and that of the newborn in cord blood immediately after birth in order to estimate the transplacental passage of this molecule.
Detailed description
* The protocole will be explain to the family in delivery room, an information note will be given, and we will let the time to think about it. * In a second time investigator will make the mother sign a consent, that participant could retract any time then. * A blood sample will be taken from the mother within 2 hours of delivery, using a standard blood test. * A sample will be taken from the infant by blood drawn from the umbilical cord (non-invasive and painless sample). * A final blood sample from your newborn will be collected at the time of the Guthrie test (systematic screening for congenital diseases) already scheduled for the new born on the third day of life. * This blood sample will be sent to the immunology laboratory of the Clermont-Ferrand University Hospital where specific biological assays will be carried out. * Blood samples will be stored for future use in studies. * A collection of data concerning the child, childbirth and the results of biological analyzes will be carried out. All data will be coded. * A phone call will be made at 3 months of life, to review the state of the child's health during his first months of life.
Interventions
BIOLOGICALBlood sampling for tryptase analysis
3 bloods test * One blood sample taking from the mother's vein punction, during the delivery. * One blood sample tanking from umbilical cord. * One blood sample taking from the baby in day 3 of life, during the Guthrie test.
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Mother-child couple * Childbirth at the Clermont-Ferrand University Hospital. * Affiliated to a social security system
Exclusion criteria
* Newborns whose holders of parental authority are protected by law (under guardianship, placed under the protection of justice) * Newborns whose holders of parental authority are under the age of 18 * Fetal pathology, excluding prematurity. * emergency caesarean section, because o life threatening condition for the fetus or the mother.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of blood tryptase | at birth (day 0) | blood sample for biomarker reflecting the mast cell activity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of blood tryptase | day 3 | blood sampling for biomarker reflecting the mast cell activity |
| Incidence of infectious disease and hospitalization | Month 3 | call phone for evaluation of medical condition for child by questionnaire about physical history in the past 3 months |
Countries
France
Contacts
Primary ContactLise LACLAUTRE
Outcome results
None listed